Ultradent Products Inc. Overview
Ultradent Products is a vertically integrated, clinician-founded American manufacturer of dental consumables, materials and small equipment, best known for Opalescence — which the company describes as the world's number one professional teeth-whitening brand — and the VALO family of LED curing lights. Built over 48 years by founder-dentist Dr. Dan Fischer, the company manufactures the overwhelming majority of its 500+ products in South Jordan, Utah, sells directly to U.S. dental practices, and reaches 130+ countries through subsidiaries and distributors. FY2025 consolidated sales were USD 372.1 million with operating income of USD 30.9 million. Its moat rests on brand equity in whitening, an unusually prolific patent culture, direct clinician relationships, and an employee-centric culture recognised by Fortune for five consecutive years. In August 2026 Mitsui Chemicals acquired Ultradent for USD 900 million, making it the U.S. anchor and global headquarters of a combined Ultradent–Kulzer oral-care platform targeting the No. 2 position in global dental materials.
What the company does. Ultradent researches, designs, manufactures, packages and distributes dental products, materials, devices and application techniques. Its portfolio spans cosmetic dentistry (professional and take-home teeth whitening; whitening toothpaste), restorative dentistry (composites, flowables, adhesives, etchants, temporary resins, finishing and polishing), tissue management (hemostatics, retraction cord), impressions (VPS/PVS materials and dispensing devices), endodontics (files, irrigants, intracanal medicaments, sealers and temporary materials), preventive and hygiene care (fluoride varnishes, prophy handpieces and angles, desensitizers, topical anesthetics), equipment (LED curing lights, soft-tissue diode lasers, protective eyewear), isolation, delivery systems (syringes and tips), and orthodontics (via its Opal Orthodontics brand).
Company's own description. Ultradent has no annual report. Its standard corporate description — repeated in every press release — characterises it as a leading developer and manufacturer of high-tech dental materials, devices and instruments worldwide, with a vision to improve oral health globally, and with a parallel commitment to improving quality of life through financial and charitable programs. The acquirer's description (Mitsui notice, 12 Jun 2026) frames Ultradent as a global leader in teeth whitening and dental restorative materials with strong design, development and manufacturing technology and established direct sales channels to dental clinics.
Independent characterisation. Ultradent is best understood as a mid-sized, premium, innovation-led consumables franchise with a razor/razor-blade overlay. Durable equipment (VALO curing lights, Gemini lasers, Ultrapro Tx handpieces, BFC3 impression gun) creates installed-base relationships in the operatory, while the vast bulk of revenue is believed to come from high-frequency consumables (whitening gels and trays, composites, cord, hemostatics, varnish, tips). Whitening is the profit and brand engine: Opalescence spans in-office (Opalescence Pro), custom-tray take-home (Opalescence Custom), prefilled trays (Opalescence Go, Home Advanced, Go Advanced) and consumer-channel toothpastes, giving Ultradent a dentist-dispensed channel into consumer aesthetics that pure materials companies lack.
Business model and revenue mix. Product sales account for effectively all revenue. There is no disclosed subscription or licensing revenue. Service revenue (equipment repair, warranty and "Equipment Services") exists but is not separately disclosed. Continuing education (live and online CE courses, the "Bridges" congress, and a new Leenie Fischer Training Center) functions as a demand-generation tool rather than a revenue line.
Value chain position. Ultradent is an integrated manufacturer: in-house R&D, chemistry formulation, injection molding (housed in the 168,000 sq ft building opened in 2023), equipment manufacturing and repair, packaging and distribution. In the U.S. it sells direct to practices (an unusual model in a market dominated by full-line distributors such as Henry Schein, Patterson and Benco), supplemented by distributor and DSO channels. Internationally it uses subsidiaries in Europe, Asia-Pacific and Latin America plus third-party distributors.
Customer types. Dentists in private practice; group practices and dental service organisations (DSOs); orthodontists and pediatric dentists; dental and veterinary laboratories; government agencies (dedicated government and formulary programs); universities and dental schools; and, for whitening toothpaste and some take-home products, consumers.
End-markets served. Global dental consumables; professional teeth whitening; dental curing lights and soft-tissue lasers; restorative materials; endodontics; preventive dentistry (fluoride), with growing adjacencies in facial esthetics (via the 2026 AAFE/StatDDS partnership).
Strategy
Stated strategy (themes; no annual report exists). Ultradent's articulated strategy, drawn from CEO interviews and press releases, rests on five themes: (1) clinician-born innovation — identifying unmet clinical needs and solving them in-house; (2) U.S. manufacturing and quality control — "the opposite of outsourcing" in the founder's framing; (3) direct relationships with clinicians, including education; (4) core values of quality, care and innovation, with a people-first culture; and (5) improving oral health globally, including charitable programs.
Mitsui's strategy for Ultradent (primary-source disclosures). Mitsui positions oral care as the core of its "medical" field and intends to make medical the third earnings pillar of Life & Healthcare Solutions (alongside vision care and agrochemicals). Ultradent provides the U.S. foundation and direct clinic channels; Kulzer provides EMEA reach and prosthetic/restorative strength. The stated objective is to elevate the group to the No. 2 position in the global dental materials market, generating more than USD 40M of annual synergy by fiscal 2030 through cross-selling, combined product development (Mitsui chemistry + Ultradent clinical insight + Kulzer restorative/prosthetic expertise) and operating-structure optimisation.
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026).
Cost programs with targets: None disclosed by Ultradent. Mitsui's USD 40M+ synergy target (by fiscal 2030) is the only quantified program.
Medium-term financial targets/guidance: Ultradent has never issued guidance. Mitsui stated the acquisition's impact on its consolidated results is under review (17 Aug 2026).
Products & Services
Specifications are taken from Ultradent press releases where available. Where the launch year or a specification is not disclosed in reviewed sources, this is stated. Pricing is not publicly disclosed in reviewed sources except for promotional shipping terms (free standard U.S. shipping on orders of USD 285+).
Whitening & Consumer Aesthetics (Opalescence family)
| Product | Description & key specifications | Target customer | Launch / latest version | Source |
|---|---|---|---|---|
| Opalescence (franchise) | Professional teeth-whitening brand; company states it has whitened 100M+ smiles and is the No. 1 professional whitening brand worldwide; vegan/gluten-free formulations across newer SKUs | Dentists dispensing to patients | c.1990; family rebranded Oct 2025 | Ultradent newsroom, 15 Oct 2025 |
| Opalescence Pro (formerly Opalescence Boost) | In-office, chairside hydrogen-peroxide whitening | General/cosmetic dentists | Renamed early 2025 | Ultradent newsroom, 15 Oct 2025 |
| Opalescence Custom (formerly Opalescence PF) | Take-home whitening gel used in custom-fabricated trays; customisable concentrations | Dentists; patients at home | Renamed 2025 | Ultradent newsroom, 15 Oct 2025 |
| Opalescence Go | Prefilled take-home whitening trays (outer + inner tray design) | Patients via dentists | Launch year not disclosed in reviewed sources | Ultradent website |
| Opalescence Home Advanced | Prefilled UltraFit tray with injection-molded gel; no outer placement tray; whitens up to 4–5 shades; 10% and 15% hydrogen peroxide; Mint; vegan, certified gluten-free and kosher | Patients via dentists | 22 Jan 2025 | Ultradent newsroom |
| Opalescence Go Advanced | Prefilled UltraFit tray, gel injection-molded onto tray; no boil-and-bite, impressions or light required; up to 5 shades; 10% (30–60 min wear) and 15% (15–20 min) HP; Cool Mint | Patients via dentists | 31 Aug 2026 | Ultradent newsroom |
| Opalescence Original Whitening Toothpaste | Daily whitening toothpaste | Consumers; dental retail | — | Ultradent newsroom, 21 Jul 2026 |
| Opalescence Sensitivity Relief Whitening Toothpaste | Whitening plus sensitivity relief | Consumers | — | Ultradent newsroom, 21 Jul 2026 |
| Opalescence Complete Whitening Toothpaste | 4-in-1 stannous fluoride formula: whitening, gum health, sensitivity, caries protection; Brilliant Mint; vegan, gluten-free | Consumers | 21 Jul 2026 | Ultradent newsroom |
| Opalescence Fluoride Free Whitening Toothpaste | Undiluted 10.5% nano-hydroxyapatite plus xylitol; no artificial flavors, dyes, SLS or fluoride; peppermint/tea tree; vegan, gluten-free, sugar-free; 30-day guarantee | Fluoride-averse consumers | 21 Jul 2026 | Ultradent newsroom |
| Limited-edition flavor ("Birthday Cake") | Limited-edition whitening flavor promoted mid-2026 | Patients | Jul 2026 | Owler (YouTube log) |
Equipment
| Product | Description & key specifications | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| VALO X | LED curing light; aerospace-grade aluminum unibody; custom LED chip; low-profile head; corded or cordless; 5-year warranty | General dentists | VALO X platform current; Colors Oct 2025 | Ultradent newsroom |
| VALO X Colors | VALO X in seven finishes (Onyx Black, Twilight Blue, Nebula Green, Stardust Gray, Horizon Red, Aurora Pink, Galaxy Purple) | General dentists | 22 Oct 2025 | Ultradent newsroom |
| VALO XG | 11.7 mm lens for larger restorations; Standard and Xtra Power modes; black-light diagnostic mode; accepts ProxiCure Ball, PointCure, TransLume, Interproximal and White Light lenses; accelerometer activation | Restorative dentists | 18 Sep 2026 | Ultradent newsroom |
| VALO XS | 9.7 mm lens for small mouths/brackets; Standard, Xtra Power and Ortho Quadrant (3-second pulses with 2-second rests) modes; black-light mode; four accessory lenses | Pediatric dentists, orthodontists | 18 Sep 2026 | Ultradent newsroom |
| Earlier VALO family (VALO, VALO Cordless, VALO Grand, VALO Ortho) | Predecessor curing lights | Dentists/orthodontists | From c.2009 | Company statements |
| Gemini diode laser | Dual-wavelength (810/980 nm) soft-tissue laser | General dentists, periodontists | Launch year not disclosed in reviewed sources | Ultradent newsroom, Apr 2024 |
| Gemini Nova | Cordless dual-wavelength (810 + 980 nm, three wavelength modes); 20 W peak super-pulsed; Bluetooth handpiece, base and foot pedal; 5.5-inch touchscreen with surgical, non-surgical, hygiene and ortho presets; optional mobile app; compatible with existing Gemini tips | General dentists | 11 Aug 2026 | Ultradent newsroom |
| Ultrapro Tx Cordless handpiece | Cordless prophy handpiece; up to 4,000 RPM; Bluetooth foot pedal; all-day charge; open design compatible with most disposable prophy angles; 2-year warranty | Hygienists | 27 Jun 2023 | Ultradent newsroom |
| BFC3 powered impression gun | Cordless motorised dispenser; fits 25/50/75 ml 1:1 or 2:1 cartridges; adjustable flow; anti-drip; auto-stop; ~60 heavy-body 50 ml cartridges per charge; 2.5-hour charge | Dentists, assistants | 16 May 2023 | Ultradent newsroom |
| Ease-In-Shields | Double-patented polycarbonate laser/curing-light filter inserts that fit most loupes and eyewear; anti-fog; certified by Laservision USA labs; 2017 Cellerant Best of Class | Laser and curing-light users | Acquired 8 May 2024 | Ultradent newsroom |
Restorative
| Product | Description & key specifications | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| FORMA S composite | Zirconia nano-hybrid; VITA classical shades; Body, Dentin, Enamel, Effect shades; flexural strength ~185.5 MPa; hardness ~64.1 HK; 74–79% filled by weight, 66–71% by volume; non-stick, slump-resistant | Restorative dentists | 29 Apr 2026 | Ultradent newsroom |
| FORMA composite | Predecessor zirconia-filled universal composite | Restorative dentists | — | Ultradent website |
| Transcend universal composite | Nanohybrid; Resin Particle Match technology; single Universal Body shade plus four dentin and two enamel shades; low abrasivity to opposing dentition | Restorative dentists | 9 May 2023 | Ultradent newsroom |
| Mosaic composite | Esthetic composite system (line referenced in catalog) | Cosmetic dentists | — | Ultradent website |
| PermaFlo flowable composite | Flowable composite family | Restorative dentists | — | Ultradent website |
| UltraSeal XT pit-and-fissure sealant | Light-cured sealant line | Pediatric/general dentists | — | Ultradent website |
| Peak Universal Bond | Universal adhesive | Restorative dentists | — | Ultradent newsroom, Apr 2024 |
| Ultra-Etch | Phosphoric acid etchant gel | Restorative dentists | — | Ultradent newsroom, Apr 2024 |
| Porcelain Etch & Silane, Consepsis | Indirect-restoration surface treatment; chlorhexidine scrub | Restorative dentists | — | Ultradent website |
| J-Temp temporary resin | Premixed light-cured temporary resin: bite ramps, temporary occlusal build-ups, clamp structure, temporary restorations, implant-coping splinting; purple for easy identification | General dentists | 1 Feb 2023 | Ultradent newsroom |
| Jiffy polishers | Composite and ceramic finishing/polishing system | Restorative dentists | — | Ultradent website |
| Jiffy Spin disks | Ultra-thin interproximal disks; aluminum-oxide coarse-to-fine plus an exclusive extra-coarse diamond disk; composite and ceramic | Restorative dentists | 6 Jun 2023 | Ultradent newsroom |
Tissue Management, Retraction & Impressions
| Product | Description | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Astringedent / Astringedent X | Ferric-sulfate/ferric-subsulfate hemostatic — Ultradent's first product | Restorative/prosthodontic dentists | 1978 (original) | Dentaltown |
| ViscoStat / ViscoStat Clear | Hemostatic gels | Dentists | — | Ultradent website |
| Ultrapak knitted retraction cord | Knitted cotton retraction cord in multiple sizes | Prosthodontic/restorative dentists | — | Ultradent newsroom, Apr 2024 |
| Thermo Clone VPS | Vinyl polysiloxane impression material with thermal-accelerated set | Dentists | — | Ultradent newsroom, May 2023 |
| Chromaclone PVS | PVS impression material line | Dentists | — | Ultradent newsroom, May 2023 |
Endodontics
| Product | Description | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Endo-Eze file systems | Endodontic instrumentation | General dentists, endodontists | — | Ultradent website |
| UltraCal XS | Calcium hydroxide intracanal paste | Endodontists | — | Ultradent website |
| File-Eze, ChlorCid | EDTA lubricant; sodium hypochlorite irrigant | Endodontists | — | Ultradent website |
| J-Temp | Also positioned under endodontic temporary restorations | Endodontists | 2,023 | Ultradent newsroom |
Prevention, Hygiene & Patient Comfort
| Product | Description | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Enamelast fluoride varnish | Patented adhesion-promoting system; seven flavors plus Flavor-Free (Vanilla and Raspberry added 2026); new unit-dose cups for bulk use | Hygienists, pediatric practices, public health | Flavors and cups 14 Apr 2026 | Ultradent newsroom |
| Gleo fluoride varnish | 5% sodium fluoride, 10 ml bulk tube; Mixed Berry and Bubble Gum; value tier for high-volume practices | Budget-conscious/high-volume clinics | 14 Apr 2026 | Ultradent newsroom |
| Ultrapro Tx disposable prophy angles (incl. Sweep DPA) | Single-use prophy angles | Hygienists | — | Ultradent newsroom, Jun 2023 |
| UltraEZ | Desensitizing gel (potassium nitrate/fluoride) | Whitening and sensitivity patients | — | Ultradent website |
| Ultracare topical anesthetic gel | 20% benzocaine; onset 15–20 seconds; dye-free Walterberry flavor | Dentists, hygienists | Reintroduced 9 Feb 2023 | Ultradent newsroom |
Delivery Systems, Isolation & Orthodontics
| Product | Description | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Syringes and tips (incl. Black Mini tip, Skini syringe) | Proprietary syringe-and-tip delivery platform underpinning many materials | All dentists | — | Ultradent newsroom, Feb 2023 |
| OpalDam | Light-cured resin barrier for isolation (e.g., during in-office whitening) | Dentists | — | Ultradent website |
| Opal Orthodontics | Orthodontic bonding and sealing materials brand | Orthodontists | — | Bitscale profile |
Services & Education
| Offering | Description | Source |
|---|---|---|
| Equipment Services | Repair and warranty servicing of curing lights, lasers, handpieces | Ultradent website |
| Ultradent Elite loyalty program | Customer loyalty/rewards program | Ultradent website |
| Dental CE & events | Online CE courses; live courses; "Bridges" congress (7 years in Brazil/North America; first European edition Lisbon, 21–23 May 2026) | Ultradent website; LinkedIn |
| Leenie Fischer Training Center | New training facility promoted 2026 | Owler (YouTube log) |
| "Grow Your Teeth Whitening Business" | Practice-building program for whitening | Ultradent website |
| DSO / Large Group, Government, University programs | Dedicated account programs | Ultradent website |
Financial Narrative
Data availability. Ultradent has never published financial statements. The only primary financial data come from Mitsui Chemicals' 12 June 2026 acquisition notice, which disclosed consolidated net assets, total assets, sales, operating income and net income attributable to owners of the parent for FY2023, FY2024 and FY2025 (fiscal years ended 31 December, USD millions). Sales and operating income exclude discontinued operations. FY2021 and FY2022 figures are not publicly disclosed; tables therefore cover FY2023–FY2025 only. Gross profit, EBITDA, pre-tax income, EPS, dividends, cash and debt, cash-flow items, capex and working capital are not publicly disclosed.
Growth (derived from Mitsui-disclosed figures)
Revenue CAGR FY2023–FY2025 (two-year, derived): 3.7%. Five-year CAGR: not calculable (FY2021–FY2022 not disclosed).
Commentary
Revenue. Sales rose from USD 346.0M (FY2023) to USD 372.1M (FY2025). FY2024 was essentially flat (+1.7%), consistent with a soft U.S. dental consumables environment in 2024, when patient-visit volumes normalised and distributors destocked; the largest listed peer, Dentsply Sirona, subsequently reported a 3% reported decline in FY2025 sales. Ultradent's re-acceleration to +5.8% in FY2025 coincides with the January 2025 Opalescence Home Advanced launch, the Opalescence rebrand, and VALO X momentum, suggesting share gains in whitening and curing lights. This outperformance against large listed peers in FY2025 is the strongest piece of evidence for franchise health in the public record.
Profitability. Operating margin sits in a narrow 7–9% band — low for a premium consumables brand (listed dental peers typically report adjusted operating margins in the mid-teens or higher). Plausible drivers include: (i) heavy U.S. manufacturing labour and a deliberately generous employee-benefit culture; (ii) a direct-sales model that carries salesforce cost which distributor-led peers externalise; (iii) significant continuing education and charitable spending; and (iv) high R&D and small-lot production across 500+ products. The FY2024 dip (operating income -12.9%) despite flat sales suggests cost inflation or investment ahead of FY2025 launches; FY2025 operating income recovered to USD 30.9M (+20.7%). Mitsui's targeted synergies of more than USD 40M per year by fiscal 2030 exceed Ultradent's entire FY2025 operating income, highlighting the margin-expansion thesis underpinning the deal.
Net income. The FY2023 net income of USD 13.2M is notably below what operating income would imply, while FY2024 net income rose 56% on lower operating income. Because sales and operating income exclude discontinued operations but net income is reported on a total basis, the most plausible explanation is losses from discontinued operations in FY2023 (and/or non-operating items). This cannot be confirmed from public sources and should be treated as an open diligence point.
Balance sheet. Ultradent is conservatively financed: equity represents 55–59% of total assets across the three years. Total assets are roughly equal to one year of sales. Equity declined in FY2024 even as the company was profitable, implying distributions to the founding family or other owners (derived; not disclosed).
Valuation reference (derived from transaction). At USD 900M, the purchase implies approximately 2.4x FY2025 sales, 29x FY2025 operating income, 37.5x FY2025 net income and 4.1x FY2025 book value. These are headline multiples on a transaction value that includes business-asset purchases and is subject to working-capital and net-debt adjustments; the final enterprise value is not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Role | Source |
|---|---|---|---|
Ultimate parent | Mitsui Chemicals, Inc. (Tokyo; TSE Prime 4183) | Group parent; >17,000 employees | Mitsui notices; Kulzer boilerplate |
Regional parent | Mitsui Chemicals America, Inc. (White Plains, NY; capital USD 5M; est. Oct 1988) | Americas regional HQ; President Antonios Grigoriou | Mitsui notice 12 Jun 2026 |
Holding company | MC Dental Holdings America, Inc. (MCDHA), 10235 South Jordan Gateway, South Jordan, UT; planned capital USD 900M; established 24 Jul 2026 (planned) | Global HQ of Mitsui's oral-care business; owns Ultradent; oversees Kulzer and group oral care; President & CEO ONO Shingo | Mitsui notice 14 Jul 2026; chemXplore |
Operating company | Ultradent Products, Inc. (South Jordan, UT) | Became a "specified subsidiary" of Mitsui via in-kind contribution on 14 Aug 2026 | Mitsui notice 21 Aug 2026 |
Ultradent subsidiaries | Germany, Italy, Spain, Brazil, Malaysia, China, Japan (named in company boilerplate); additional market presence in Australia, Korea, France, Netherlands, Croatia, Türkiye, Latin America | Built In; Ultradent website | — |
Ultradent acquired units | Azena Medical, LLC (Walnut Creek, CA; acquired Jun 2026); Ease-In-Shields product line (May 2024); reported majority stake in i-dental (date unconfirmed) | Ultradent newsroom; Dentistry Today | — |
Sister companies (Mitsui oral care) | Kulzer GmbH (Hanau, Germany; >1,200 employees, 24 locations); Sun Medical Co., Ltd. (Japan) | Ultradent newsroom 12 Jun 2026 | — |
Product Category Details
| Product category (analyst construct) | Contents | Flagship brands |
|---|---|---|
Whitening & consumer aesthetics | In-office, take-home, prefilled tray whitening; whitening toothpaste | Opalescence Pro, Custom, Go, Go Advanced, Home Advanced, Opalescence toothpastes |
Equipment | LED curing lights, diode lasers, prophy handpieces, impression dispensers, protective eyewear | VALO X/XS/XG, Gemini/Gemini EVO/Gemini Nova, Ultrapro Tx, BFC3, Ease-In-Shields |
Restorative | Composites, flowables, sealants, adhesives, etchants, temporaries, finishing/polishing | FORMA, FORMA S, Transcend, PermaFlo, UltraSeal XT, Peak Universal Bond, Ultra-Etch, J-Temp, Jiffy |
Tissue management & impressions | Hemostatics, retraction cord, VPS/PVS impression materials | Astringedent, ViscoStat, Ultrapak, Thermo Clone, Chromaclone |
Endodontics | Files, irrigants, medicaments, temporaries | Endo-Eze, UltraCal XS, File-Eze, ChlorCid, J-Temp |
Prevention & hygiene | Fluoride varnish, prophy angles, desensitizers, topical anesthetic | Enamelast, Gleo, Ultrapro Tx DPAs, UltraEZ, Ultracare |
Delivery systems & isolation | Syringes, tips, light-cured dam | Skini syringes, Black Mini tips, OpalDam |
Orthodontics | Bonding and sealing materials | Opal Orthodontics brand |
Income Statement and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated sales, continuing ops (USD Mn) | 346.0 | 351.8 | 372.1 |
Consolidated operating income, continuing ops (USD Mn) | 29.4 | 25.6 | 30.9 |
Net income attributable to owners of parent (USD Mn) | 13.2 | 20.6 | 24.0 |
Operating margin (%, derived) | 8.5 | 7.3 | 8.3 |
Net margin (%, derived) | 3.8 | 5.9 | 6.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Sales growth YoY (%) | 1.7 | 5.8 |
Operating income growth YoY (%) | -12.9 | 20.7 |
Net income growth YoY (%) | 56.1 | 16.5 |
Financial Analysis
| Line item | Status |
|---|---|
EPS (basic/diluted) | Not publicly disclosed (derived reference only: FY2025 net income ÷ 1,318k shares acquired ≈ USD 18.2 per share; share count as reported by acquirer, may not equal weighted average outstanding) |
Capex | Not publicly disclosed (qualitative: major campus expansion — 168,000 sq ft building completed May 2023) |
Dividends paid / distributions to owners | Not publicly disclosed (note: equity fell USD 20.7M in FY2024 despite USD 20.6M of net income, implying distributions or other equity reductions of roughly USD 41M that year — derived, cause not disclosed) |
Buybacks | Not applicable / not disclosed |
Balance Sheet and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated total assets (USD Mn) | 376.5 | 365.1 | 386.5 |
Consolidated net assets / equity (USD Mn) | 221.7 | 201.0 | 220.5 |
Total liabilities (USD Mn, derived: assets minus net assets) | 154.8 | 164.1 | 166.0 |
Equity ratio (%, derived) | 58.9 | 55.1 | 57.1 |
Liabilities to equity (x, derived) | 0.70 | 0.82 | 0.75 |
Line item | Status | — | — |
Total debt (short/long split) | Not publicly disclosed (purchase price adjusts for "net interest-bearing debt", confirming some debt and/or cash balances exist) | — | — |
Goodwill & intangibles | Not publicly disclosed (pre-acquisition); Mitsui purchase-price allocation pending — impact "under review" per 17 Aug 2026 notice | — | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansReturns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
ROE on average equity (%) | 9.7 | 11.4 |
ROA on average assets (%) | 5.6 | 6.4 |
Asset turnover (x) | 0.95 | 0.99 |
Ratio | Status | — |
ROIC | Not calculable (invested capital/debt not disclosed) | — |
Debt/equity | Not publicly disclosed (total liabilities/equity shown above as proxy) | — |
Geographic Revenue
| Indicator | Detail | Source / year |
|---|---|---|
Export share | Company stated at its 40th anniversary that it exported ~70% of its products to 100+ countries | Dentaltown, 2018 |
Majority abroad | Incisal Edge (via Ultradent) stated Ultradent sells the majority of its products abroad, in 130 countries | Ultradent newsroom, Apr 2024 |
Acquirer characterisation | Mitsui describes Ultradent's sales as occurring primarily in the Americas, and JCR notes it operates mainly in the U.S. | Mitsui release 17 Aug 2026; JCR 15 Jun 2026 |
Reconciliation | "Products" (units/SKU count) exported versus revenue share likely differ; the U.S. direct channel probably yields higher revenue per unit than distributor-served export markets. Treat the U.S./Americas as the largest revenue region (acquirer view) while acknowledging a large international footprint by units | Analyst assessment |
International bases | Subsidiaries in Germany, Italy, Spain, Brazil, Malaysia, China, Japan; country sites for Australia, Korea, France, Netherlands, Croatia, Türkiye and Latin America | Built In; Ultradent website |
Complementarity | Mitsui explicitly positions Ultradent (Americas) and Kulzer (EMEA) as geographically complementary | Mitsui notice 12 Jun 2026 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable — Ultradent shares never traded publicly |
Valuation multiples (transaction-implied, derived) | EV/Sales ~2.4x FY2025; EV/EBIT ~29.1x FY2025; P/E ~37.5x FY2025; P/B ~4.1x FY2025 — on the USD 900M headline transaction value (includes business-asset costs; subject to adjustments) |
Analyst consensus | Not applicable (no coverage of Ultradent); Mitsui Chemicals is covered by sell-side analysts |
Dividend history / policy | Not publicly disclosed (private distributions inferred from FY2024 equity decline — derived) |
Credit ratings (Moody's/S&P/Fitch) | Ultradent: none. Parent Mitsui Chemicals: JCR stated on 15 Jun 2026 that the acquisition had no immediate impact on its existing rating |
Per-Share Data
| Metric | FY2025 |
|---|---|
Net income per share acquired (USD, derived) | 18.2 |
Book value per share acquired (USD, derived) | 167.3 |
Transaction value per share acquired (USD, derived) | 682.9 |
Analyst Conclusions
Management guidance. None published by Ultradent. Mitsui's stated goals: transfer the oral-care global HQ to Utah; achieve >USD 40M annual synergies by fiscal 2030; lift the group to No. 2 in global dental materials; and develop an integrated growth strategy, business plan, KPIs and synergy roadmap for Ultradent and Kulzer. The impact on Mitsui's consolidated results was "under review" as of 17 Aug 2026.
Consensus growth expectations. Not available (no coverage). Base-rate reference: the professional whitening market is forecast to grow ~5.7% annually to 2030; Ultradent grew 5.8% in FY2025.
Bull case.
-
Synergies transform margins. USD 40M+ of synergy on a USD 372M revenue base could more than double Ultradent's FY2025 operating income of USD 30.9M if realised substantially within Ultradent.
-
Product engine is accelerating. The 2025–2026 launch slate (UltraFit trays, FORMA S, Gemini Nova, VALO XS/XG, new toothpastes) builds on a FY2025 growth rebound that outpaced listed peers.
-
Global distribution unlocked. Kulzer's EMEA network and Mitsui's Asian presence can scale Opalescence and VALO in markets where Ultradent is under-penetrated.
Bear case.
-
Paid-up price. At ~29x FY2025 operating income, the deal leaves little room for integration slippage; peer impairments (Dentsply Q4 2025) show the downside.
-
Culture is the asset at risk. Ultradent's direct, clinician-centric, high-retention culture underpins innovation; combining with a restructured Kulzer under a chemicals conglomerate could erode it.
-
Structural margin ceiling. U.S. manufacturing, direct sales and a vast SKU base have historically capped operating margin near 8%; synergy targets may prove harder to reach than cross-selling theory implies, particularly with overlapping composite and adhesive lines.
Key catalysts and monitorables (next 12 months).
Concluding analyst verdict. Ultradent enters its 49th year as one of the dental industry's most distinctive franchises — and, for the first time, as part of a larger whole. The public evidence portrays a company with exceptional brand assets (Opalescence, VALO), a genuinely prolific innovation culture, an unusually loyal workforce and a conservative balance sheet, but with mediocre financial productivity: an 8.3% operating margin on USD 372.1M of FY2025 sales is modest for a premium consumables brand. The FY2025 rebound to 5.8% growth, achieved while the largest listed peer contracted, is the clearest sign that the franchise is healthy and that the 2025–2026 product cycle is working.
Mitsui Chemicals paid a full price — roughly 2.4x sales and 29x operating income — and its investment case is explicitly about margin expansion and geographic leverage rather than standalone growth. The decision to relocate the group's oral-care headquarters to South Jordan and to make Dirk Jeffs CEO of both Ultradent and Kulzer is a strong vote of confidence in Ultradent's management model, effectively making the acquired company the integrator. That inversion is the deal's most important feature and its greatest risk: if Ultradent's culture and direct clinical relationships propagate into Kulzer's EMEA business, the No. 2 ambition and USD 40M synergy target are plausible; if bureaucracy flows the other way, the premium multiple will be hard to defend.
On balance, the strategic logic is sound, the product pipeline is strong, and the leadership arrangement is well designed. The key uncertainties are execution and transparency: until Mitsui discloses Ultradent's post-acquisition contribution and integration KPIs, external observers must rely on product cadence, retention and culture rankings as leading indicators. Our assessment: constructive on the franchise, neutral-to-cautious on near-term financial returns to the acquirer, with the 2027 integration milestones the decisive test.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education |
|---|---|---|---|---|
Dirk Jeffs | President & CEO, Ultradent; concurrently CEO of Kulzer Group (from Aug 2026) | Joined 1996 (some sources say 1995); President since Apr 2016; CEO since May 2020 | International Sales Manager; marketing responsibilities added later; led satellite operations in Europe, Japan, China and Brazil | MBA, Brigham Young University |
Dr. Dan Fischer, DDS | Founder & CEO Emeritus | Founder 1978; CEO 1978–2020 | Practising dentist; inventor (Astringedent, Opalescence and many others); Incisal Edge Dental Innovators Hall of Fame 2024; remains involved in R&D, outreach and lecturing | DDS |
Dr. Jaleena Fischer-Jessop | Chief Clinical Officer (title as of 2026) | Formerly VP of Clinical Affairs | Practising dentist; founder's daughter; clinical spokesperson for whitening and J-Temp | — |
Neil Jessop | Senior Vice President, Research & Development | Long-tenured (exact start not disclosed) | Leads product development (Transcend, VALO X Colors, VALO XS/XG) | — |
Steve Clark | General Manager, North America | Since Apr 2023; ~20 years at Ultradent | Former Director of U.S. Sales; also leads consumer retail sales and client relations | — |
Sean Kennedy | Senior Vice President, Marketing | Since Apr 2023; 15+ years in Ultradent marketing | Former Senior Director, U.S. Marketing | — |
Scot Andersen | Vice President, Business Development | Cited 2024 | Led Ease-In-Shields acquisition | — |
Neil Poulsen | Senior Category Manager (whitening) | Cited 2025 | Opalescence Home Advanced launch | — |
CFO | Not publicly identified in reviewed sources | — | — | — |
“—” = not publicly disclosed.
Executive Leadership Team — ONO Shingo
| Name | Role | Source |
|---|---|---|
ONO Shingo | President & CEO, MC Dental Holdings America; General Manager, Mitsui Oral Care Business Division (relocating to the U.S.) | Mitsui release 17 Aug 2026; chemXplore |
Chris Holden | Chief Strategy and Integration Officer (CSTIO), MCDHA; formerly CEO of Kulzer GmbH | Mitsui release 17 Aug 2026 |
Hiromi Hayashida | Business Sector President, Life & Healthcare Solutions, Mitsui Chemicals | Ultradent newsroom 12 Jun 2026 |
Antonios Grigoriou | President, Mitsui Chemicals America; Business Sector Vice President, Life & Healthcare Solutions | Mitsui notice 12 Jun 2026 |
ICHIMURA Satoshi | Representative Director, President & CEO, Mitsui Chemicals, Inc. | Mitsui notice |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Apr 2016 | Jeffs named President | Succession planning under Fischer |
May 2020 | Jeffs named CEO; Fischer becomes CEO Emeritus | Founder transition at COVID onset |
27 Apr 2023 | Clark to GM North America; Kennedy to SVP Marketing; Phillips retires | Commercial reorganisation |
2025–2026 | Jaleena Fischer-Jessop referred to as Chief Clinical Officer (previously VP Clinical Affairs) | Title elevation (exact date not disclosed) |
14–17 Aug 2026 | Jeffs becomes concurrent CEO of Kulzer Group; ONO Shingo heads MCDHA; Holden becomes CSTIO | Post-merger integration structure |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
MC Dental Holdings America, Inc. (100% owned by Mitsui Chemicals America, Inc., itself 100% owned by Mitsui Chemicals, Inc.) | 100% (since 14 Aug 2026; transferred by in-kind contribution) | Mitsui notice 21 Aug 2026 |
Pre-deal: Dr. Dan Fischer and other shareholders | Fischer was the major shareholder; exact ratio not disclosed due to confidentiality | Mitsui notice 12 Jun 2026 |
Institutional ownership (top 10) | Not applicable — Ultradent had no public float and never raised outside funding | Prospeo directory; Mitsui notice |
Insider ownership | 0% post-acquisition (100% Mitsui) | — |
Competitive Landscape
Key Competitors
| Competitor | Listing | Areas of overlap with Ultradent | Relative positioning |
|---|---|---|---|
Dentsply Sirona | Nasdaq: XRAY | Restoratives, endodontics, curing lights, preventive, whitening | Far larger, broad-line; FY2025 sales USD 3.68B (-3% reported); goodwill impairments; dividend eliminated; FY2026 guide USD 3.5–3.6B |
Envista Holdings (Kerr, Nobel Biocare, Ormco) | NYSE: NVST | Kerr restoratives, endodontics, curing lights | — |
Solventum (former 3M Health Care, incl. Oral Care) | NYSE: SOLV | Composites (Filtek), adhesives, impressions, curing lights, fluoride varnish | Dental not separately reported in reviewed sources; benchmark for materials science |
Ivoclar Vivadent | Private (Liechtenstein) | Composites, adhesives, curing lights, whitening | Premium European rival; financials not publicly disclosed |
GC Corporation | Private (Japan) | Restoratives, preventive, impressions | — |
Kulzer (Mitsui) | Sister company since 2026 | Composites, adhesives, impressions, prosthetics | Formerly a competitor; now integration partner |
Philips (Zoom whitening) | Euronext: PHIA | Professional whitening | Leading rival in in-office whitening |
DenMat Holdings | Private | Professional whitening, restoratives | Cited as leading professional whitening player |
FGM Dental Group | Private (Brazil) | Whitening, restoratives (strong in Latin America) | Cited as leading professional whitening player |
SDI Limited | ASX: SDI | Whitening (Pola), composites, varnish | Smaller listed comparable |
Septodont | Private (France) | Endodontics, anesthetics, preventive | Specialist competitor |
Biolase and other laser makers | Various | Diode/soft-tissue lasers | Competes with Gemini line |
Consumer brands (Colgate, P&G Crest, Haleon) | Listed | Whitening toothpaste and strips | Compete for consumer whitening wallet |
Peer Comparison FY2025
| Metric | Ultradent | Dentsply Sirona |
|---|---|---|
Revenue | USD 372.1M (FY2025, continuing ops) | USD 3.68B (FY2025) |
Revenue growth | +5.8% (FY2025) | -3.0% reported; -4.3% constant currency (FY2025) |
Operating margin | 8.3% (FY2025, derived) | — |
Net result | USD 24.0M net income (FY2025) | Q4 2025 net loss USD 146M |
Free cash flow | — | USD 104M (FY2025) |
“—” = not publicly disclosed.
